/PRNewswire/ -- MGI, part of global genomics leader BGI Group, today announced the commercial availability of its sequencing instruments and reagent kits in...
Shawn BakerBGI is hitting ILMN where they live! But I thought PacBio was going to be the one to apply pricing pressure...
MGI Announces Commercial Launch of its CoolMPS™ Chemistry-based DNBSEQ™ Sequencers in the United States
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Q2 2018 Earnings Conference Call - Final Transcript Good day, ladies and gentlemen, and welcome to the Pacific Biosciences of California Second Quarter 2018 Earnings Conference Call. At this...
San Diego company is developing a platform to deliver accurate, fast, low-cost genetic testing for medical diagnosis
Shawn BakerWill San Diego’s Omniome be the next sequencing startup to hit the market? $60M has got to help.
Sequencing startup Omniome pulls in $60 million as it nears initial instrument production
Here’s my take on what we might see in 2020 for the sequencing platform market. This isn’t specifically about JPM, but I wanted to get this out ahead of the conference since it’s obviously one of t…
Shawn BakerCheck out my 2020 Sequencing Predictions before JPM makes them all obsolete.
Shawn BakerMy sequencing platform predictions for the upcoming year Not specific to JPM, but this will start looking stale after next week. (Highlights to follow for those who don’t like to leave Twitter.)
As a cancer patient, she had received cord-blood cells from an anonymous donor. The DNA from those cells led her to him.
Shawn BakerA Woman Found Her Cord-Blood Donor From a DNA Test - The Atlantic theatlantic.com/science/archiv…
I would have never guessed that spit samples include white blood cells or that the extracted sample would be purely from one genome.
SAN JOSE, Calif., Jan. 9, 2019 /PRNewswire/ -- MGI, a subsidiary of global genomics leader BGI Group, announced pricing and its first early access customer for ...
Shawn BakerFrom BGI/MGI at JPM - "In the China market, MGI has six different sequencers licensed, and a market share of 35%."
The kindest thing I can say about this statement is that it "doesn't match my channel checks".
A tech company launched by one of Illumina’s founding scientists is stepping out of stealth mode today with gene sequencing software it says can monitor the spread of infectious disease — particularly fast-evolving strains difficult to keep tabs on...